Industry
Biotechnology
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Loading...
Open
1.50
Mkt cap
42M
Volume
8.9K
High
1.72
P/E Ratio
-6.52
52-wk high
3.30
Low
1.50
Div yield
N/A
52-wk low
1.46
Portfolio Pulse from Benzinga Newsdesk
November 14, 2023 | 9:59 pm
Portfolio Pulse from Lisa Levin
October 17, 2023 | 5:42 pm
Portfolio Pulse from Benzinga Insights
October 17, 2023 | 5:31 pm
Portfolio Pulse from Benzinga Newsdesk
October 06, 2023 | 8:07 pm
Portfolio Pulse from Benzinga Newsdesk
October 03, 2023 | 3:52 pm
Portfolio Pulse from Benzinga Newsdesk
September 29, 2023 | 11:23 am
Portfolio Pulse from Benzinga Newsdesk
September 25, 2023 | 10:10 am
Portfolio Pulse from Benzinga Newsdesk
September 21, 2023 | 3:49 pm
Portfolio Pulse from Happy Mohamed
September 20, 2023 | 8:30 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.